259 related articles for article (PubMed ID: 33826022)
41. Access to HIV Pre-exposure Prophylaxis in Practice Settings: a Qualitative Study of Sexual and Gender Minority Adults' Perspectives.
Sun CJ; Anderson KM; Bangsberg D; Toevs K; Morrison D; Wells C; Clark P; Nicolaidis C
J Gen Intern Med; 2019 Apr; 34(4):535-543. PubMed ID: 30719647
[TBL] [Abstract][Full Text] [Related]
42. Two-Way Short Message Service (SMS) Communication May Increase Pre-Exposure Prophylaxis Continuation and Adherence Among Pregnant and Postpartum Women in Kenya.
Pintye J; Rogers Z; Kinuthia J; Mugwanya KK; Abuna F; Lagat H; Sila J; Kemunto V; Baeten JM; John-Stewart G; Unger JA
Glob Health Sci Pract; 2020 Mar; 8(1):55-67. PubMed ID: 32139420
[TBL] [Abstract][Full Text] [Related]
43. "
Mwongeli N; Wagner AD; Dettinger JC; Pintye J; Brown Trinidad S; Awuor M; Kimemia G; Ngure K; Heffron RA; Baeten JM; Mugo N; Bukusi EA; Kinuthia J; Kelley MC; John-Stewart GC; Beima-Sofie KM
J Int Assoc Provid AIDS Care; 2022; 21():23259582221111068. PubMed ID: 35776525
[No Abstract] [Full Text] [Related]
44. Measuring the performance of computer vision artificial intelligence to interpret images of HIV self-testing results.
Roche SD; Ekwunife OI; Mendonca R; Kwach B; Omollo V; Zhang S; Ongwen P; Hattery D; Smedinghoff S; Morris S; Were D; Rech D; Bukusi EA; Ortblad KF
Front Public Health; 2024; 12():1334881. PubMed ID: 38384878
[TBL] [Abstract][Full Text] [Related]
45. Test and Prevent: Evaluation of a Pilot Program Linking Clients With Negative HIV Test Results to Pre-exposure Prophylaxis in Zimbabwe.
Stankevitz K; Nhamo D; Murungu J; Ridgeway K; Mamvuto T; Lenzi R; Lydon M; Katsande N; Mahaka I; Hoke T
Glob Health Sci Pract; 2021 Mar; 9(1):40-54. PubMed ID: 33795361
[TBL] [Abstract][Full Text] [Related]
46. Design and evaluation of strategies to implement HIV prevention interventions for pregnant women in community pharmacy settings in western Kenya: a mixed-methods study protocol.
Mugambi ML; Baeten JM; Kinuthia J; Hauber B; Weiner BJ; John-Stewart G; Barnabas RV
BMJ Open; 2021 Dec; 11(12):e052311. PubMed ID: 34911715
[TBL] [Abstract][Full Text] [Related]
47. A community-based dynamic choice model for HIV prevention improves PrEP and PEP coverage in rural Uganda and Kenya: a cluster randomized trial.
Kakande ER; Ayieko J; Sunday H; Biira E; Nyabuti M; Agengo G; Kabami J; Aoko C; Atuhaire HN; Sang N; Owaranganise A; Litunya J; Mugoma EW; Chamie G; Peng J; Schrom J; Bacon MC; Kamya MR; Havlir DV; Petersen ML; Balzer LB;
J Int AIDS Soc; 2023 Dec; 26(12):e26195. PubMed ID: 38054535
[TBL] [Abstract][Full Text] [Related]
48. "I just believe there is a risk" understanding of undetectable equals untransmissible (U = U) among health providers and HIV-negative partners in serodiscordant relationships in Kenya.
Ngure K; Ongolly F; Dolla A; Awour M; Mugwanya KK; Irungu E; Mugo N; Bukusi EA; Morton J; Odoyo J; Wamoni E; Barnabee G; Peebles K; O'Malley G; Baeten JM;
J Int AIDS Soc; 2020 Mar; 23(3):e25466. PubMed ID: 32144888
[TBL] [Abstract][Full Text] [Related]
49. Trends in the Number and Characteristics of HIV Pre-Exposure Prophylaxis Providers in the United States, 2014-2019.
Zhu W; Huang YA; Kourtis AP; Hoover KW
J Acquir Immune Defic Syndr; 2021 Nov; 88(3):282-289. PubMed ID: 34651603
[TBL] [Abstract][Full Text] [Related]
50. A community-based mobile clinic model delivering PrEP for HIV prevention to adolescent girls and young women in Cape Town, South Africa.
Rousseau E; Bekker LG; Julies RF; Celum C; Morton J; Johnson R; Baeten JM; O'Malley G
BMC Health Serv Res; 2021 Aug; 21(1):888. PubMed ID: 34454505
[TBL] [Abstract][Full Text] [Related]
51. Key barriers and enablers associated with uptake and continuation of oral pre-exposure prophylaxis (PrEP) in the public sector in Zimbabwe: Qualitative perspectives of general population clients at high risk for HIV.
Gombe MM; Cakouros BE; Ncube G; Zwangobani N; Mareke P; Mkwamba A; Prescott MR; Bhatasara T; Murwira M; Mangwiro AZ; Prust ML
PLoS One; 2020; 15(1):e0227632. PubMed ID: 31931514
[TBL] [Abstract][Full Text] [Related]
52. Understanding adaptive responses in PrEP service delivery in Belgian HIV clinics: a multiple case study using an implementation science framework.
Vanhamel J; Reyniers T; Vuylsteke B; Callens S; Nöstlinger C; Huis In 't Veld D; Kenyon C; Van Praet J; Libois A; Vincent A; Demeester R; Henrard S; Messiaen P; Allard SD; Rotsaert A; Kielmann K
J Int AIDS Soc; 2024 Jul; 27 Suppl 1(Suppl 1):e26260. PubMed ID: 38965986
[TBL] [Abstract][Full Text] [Related]
53. The perspectives of street-involved youth who use drugs regarding the acceptability and feasibility of HIV pre-exposure prophylaxis: a qualitative study.
Dahlby L; Boyd J; Knight R; Philbin M; Small W; Kerr T; McNeil R
AIDS Care; 2023 Apr; 35(4):480-487. PubMed ID: 35698454
[TBL] [Abstract][Full Text] [Related]
54. Support and perceived barriers to implementing pre-exposure prophylaxis screening and dispensing in pharmacies: Examining concordance between pharmacy technicians and pharmacists.
Hopkins R; Josma D; Morris J; Klepser DG; Young HN; Crawford ND
J Am Pharm Assoc (2003); 2021; 61(1):115-120. PubMed ID: 33214059
[TBL] [Abstract][Full Text] [Related]
55. Patient and Provider Perspectives on a Novel, Low-Threshold HIV PrEP Program for People Who Inject Drugs Experiencing Homelessness.
Bazzi AR; Shaw LC; Biello KB; Vahey S; Brody JK
J Gen Intern Med; 2023 Mar; 38(4):913-921. PubMed ID: 35614171
[TBL] [Abstract][Full Text] [Related]
56. Unlocking HIV Pre-Exposure Prophylaxis Delivery: Examining the Role of HIV Providers in Pre-Exposure Prophylaxis Care.
Kenison TC; Badenhop B; Safo S
AIDS Patient Care STDS; 2020 Jun; 34(6):251-258. PubMed ID: 32484745
[TBL] [Abstract][Full Text] [Related]
57. Risk factors for loss to follow-up among at-risk HIV negative men who have sex with men participating in a research cohort with access to pre-exposure prophylaxis in coastal Kenya.
Wahome EW; Graham SM; Thiong'o AN; Mohamed K; Oduor T; Gichuru E; Mwambi J; van der Elst EM; Sanders EJ
J Int AIDS Soc; 2020 Oct; 23 Suppl 6(Suppl 6):e25593. PubMed ID: 33000889
[TBL] [Abstract][Full Text] [Related]
58. Alignment of adherence and risk for HIV acquisition in a demonstration project of pre-exposure prophylaxis among HIV serodiscordant couples in Kenya and Uganda: a prospective analysis of prevention-effective adherence.
Haberer JE; Kidoguchi L; Heffron R; Mugo N; Bukusi E; Katabira E; Asiimwe S; Thomas KK; Celum C; Baeten JM
J Int AIDS Soc; 2017 Jul; 20(1):21842. PubMed ID: 28741331
[TBL] [Abstract][Full Text] [Related]
59. Implementation of pre-exposure prophylaxis for human immunodeficiency virus infection: progress and emerging issues in research and policy.
Cáceres CF; Borquez A; Klausner JD; Baggaley R; Beyrer C
J Int AIDS Soc; 2016; 19(7(Suppl 6)):21108. PubMed ID: 27760685
[TBL] [Abstract][Full Text] [Related]
60. Community pharmacy delivered PrEP to STOP HIV transmission: An opportunity NOT to miss!
Lopez MI; Grant RM; Dong BJ
J Am Pharm Assoc (2003); 2020; 60(4):e18-e24. PubMed ID: 32165026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
